Key facts
- This page summarizes Cafico Trust Co Ltd's Form 3 filing for Mural Oncology plc (MURA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Nov 2023, 16:18.
Cafico Trust Co Ltd - 31 Oct 2023 Form 3 Insider Report for Mural Oncology plc (MURA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MURA
- Reported as of
- 31 Oct 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Mairead Lyons
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Cafico Trust Co Ltd filed Form 3 for Mural Oncology plc (MURA) on 07 Nov 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MURA
holding
Ordinary Shares, nominal value $1.00 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
MURA
holding
Euro Deferred Shares, nominal value 1.00 Euro per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,000
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F2
MURA
holding
Preferred Share, nominal value $0.01 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The ordinary shares of Mural Oncology plc ("Mural"), nominal value $1.00 per share, beneficially owned by Cafico Trust Company Limited, constitute 100% of the ordinary shares of Mural. As of the date of this report, Alkermes plc ("Alkermes") has announced its intention to separate its oncology business from the rest of Alkermes by means of a declaration of a dividend in specie, to be effected by the transfer of the oncology business from Alkermes to Mural and the issuance by Mural of ordinary shares to Alkermes shareholders.
Footnote F2
In connection with the separation of the oncology business, Cafico Trust Company Limited also owns (i) 25,000 Euro deferred shares, nominal value 1.00 Euro per share, and (ii) one preferred share, nominal value $0.01, of Mural.